偏头痛发病机制及生物标志物研究进展  

Research advances in the pathogenesis and biomarkers of migraine

作　　者：毛西京[1] 朱博驰(综述)[1] 于挺敏(审校)[1] MAO Xijing;ZHU Bochi;YU Tingmin(The Second Hospital of Jilin University,Changchun 130000,China)

机构地区：[1]吉林大学第二医院,吉林长春130000

出　　处：《中风与神经疾病杂志》2024年第7期586-588,F0002,共4页Journal of Apoplexy and Nervous Diseases

摘　　要：偏头痛是一种具有多种亚表型的异质性疾病,其诊断主要基于临床标准,缺乏特异性的生物标志物进行客观评估,影响了偏头痛的精确诊断、治疗选择以及预后评估。近年来偏头痛在遗传、生化、影像等方面研究取得重大进展,为临床诊断及治疗偏头痛提供了客观的检测指标。如能在临床工作中选择特异性、敏感性、易检测、可行性高的标志物将推动偏头痛早期诊断、精准化治疗的步伐。Migraine is a heterogeneous disease with various subtypes,and the diagnosis of migraine mainly relies on clinical criteria.The lack of specific biomarkers for objective assessment impacts the precise diagnosis,treatment selection,and prognostic assessment of migraine.In recent years,great progress has been made in migraine in terms of genetics,biochemistry,and imaging,which provides objective indicators for the clinical diagnosis and treatment of migraine.Identifying specific,sensitive,easily detectable,and highly feasible markers in clinical practice will accelerate the early diagnosis and precise treatment of migraine.

关 键 词：偏头痛 生物标志物 神经元 胶质细胞 

分 类 号：R747.2[医药卫生—神经病学与精神病学]